ProSavin is a product of Oxford Biomedica and the results mentioned are pre clinical, today it entered Phase I.

ProSavin doesn't use a growth agent, (e.g. Neuturin), rather "ProSavin is administered locally to the region of the brain called the striatum, converting the target cells into a replacement dopamine factory within the brain, thus replacing the patient's own lost source of the neurotransmitter".

The Neurologix procedure delivers a gene (glutamic acid decarboxylase, or GAD) to the subthalamic nucleus of the brain, where it makes an inhibitory neurotransmitter called GABA that helps to quiet the abnormal brain activity that is correlated with motor deficits characterizing Parkinson's disease.

See http://www.oxfordbiomedica.co.uk/prosavin.htm for more details.

Interestingly Neurologix has been granted fast track status by the FDA.

Neurologix, Ceregene and Oxford Biomedica all have different approaches and this is what makes the gene therapy field so exciting. Not to mention Spheramine ...

Take care,
Neil.